Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

STAMFORD, Conn., April 04, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc.( LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that interim clinical data from the ongoing Phase 1 clinical trial for LOXO-292, the company’s highly selective RET inhibitor, will be presented in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1 - 5, 2018 in Chicago, Illinois.

The presentation is entitled “A Phase 1 Study of LOXO-292, A Potent and Highly Selective RET Inhibitor, in Patients with RET-Altered Cancers.”